Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 296-301

  Joulia, J M ^a,b   Pinguet, F ^a   Ychou, M ^a   Duffour, J ^a   Astre, C ^a   Bressolle, F ^a  

^a Anticancer Center   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

5 fluorouracil; Metastatic colorectal cancer; Parotid saliva; Pharmacokinetics; Plasma

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SALIVA LEVEL; FEMALE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; PRIORITY JOURNAL;

ADULT; AGED; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SALIVA;

EID: 0033083155     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00318-9     Document Type: Article

References (33)

1. Door RT, Fritz WL. Cancer Chemotherapy Handbook. Amsterdam, Elsevier/North-Holland, 1980, 435.
2. Yoshida T., Araki E., Iigo M., et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 26:1990;352-354.
3. Lokich J.J., Ahlgren J.D., Gullo J.J., Philips J.A., Fryer J.G. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol. 7:1989;425-432.
4. The advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1992, 10, 896-903.
5. Johnson P.W.M., Thompson P.I., Seymour M.T., et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer. 64:1991;603-605.
6. de Gramont A., Krulik M., Cady J., et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 24:1988;1499-1503.
7. de Gramont A., Bosset J.F., Milan C., et al. A prospective randomized trial comparing 5FU bolus with low dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc ASCO. 14:1995;A455.
8. Erlichman C., Fine S., Elhakim T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep. 70:1986;903-904.
9. Harris B.E., Song R.L., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for a circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
10. Petit E., Milano G., Levi F., Thyss A., Bailleul F., Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 48:1988;1676-1679.
11. Thyss A., Milano G., Renee N., Vallicioni J., Schneider M., Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol. 16:1986;64-66.
12. Van Groeningen C.J., Pinedo H.M., Heddes J., et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48:1988;6956-6961.
13. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206.
14. Trump D., Egorin M.J., Forrest A., Willson J.K.V., Remick S., Tutsch K. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 9:1991;2027-2035.
15. Schalhorn A., Kühl M. Clinical pharmacokinetics of fluorouracil and folinic acid Semin Oncol. 19:1992;82-92.
16. Gamelin E.C., Danquechin-Dorval E.M., Dumesnil Y.F., et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer. 77:1996;441-451.
17. Joulia J.M., Pinguet F., Grosse P.Y., et al. Pharmacokinetic of 5-fluorouracil (5-FU) in patients with colorectal cancer receiving 5-FU bolus plus continuous infusion with high dose folinic acid (LV5FU2). Anticancer Res. 17:1997;2727-2730.
18. Seymour M.T., Patel N., Johnston A., Joel S.P., Slevin M.L. Lack of effect of interferon α2a upon fluorouracil pharmacokinetics. Br J Cancer. 70:1994;727-728.
19. Milano G., Etienne M.C., Cassuto-Viguier E., et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 10:1992;1171-1175.
20. Collin J.M., Dedrick R.L., King F.G., Speyer J.L., Myers C.E. Non-linear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharm Ther. 28:1980;235-246.
21. Pinedo H.M., Peters G.J. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 6:1988;1653-1664.
22. Santini J., Milano G., Thyss A., et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 59:1989;287-290.
23. Arbuck S.G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 63:1989;1036-1044.
24. Cascinu S., Fedeli A., Fideli S.L., Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Oral Oncol. 30B:1994;234-236.
25. Duffour J, Ychou M, Kramar A, Pinguet F, Joulia JM, Bressolle F. Individual pharmacokinetic modulated 5FU-dose-adaptation schedule of LV5FU2. Proc 8th World Congress Int Gastro-Surgical Club. 1998, Strasbourg, 15-18 April, France.
26. Joulia J.M., Pinguet F., Grosse P.Y., Astre C., Bressolle F. Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography. Application to a pharmacokinetic study. J Chromatogr B. 692:1997;427-435.
27. Pk-fit Computer Program, Version 1.1. 1997, RDPP, Montpellier, France.
28. Celio L.A., Di Gregorio G.J., Ruch E., Pace J., Piraino A.J. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol. 24:1983;261-266.
29. Milano G., Thyss A., Santini J., Frenay E., Schneider M., Demard F. Salivary passage of 5-fluorouracil during continuous infusion. Cancer Chemother Pharmacol. 24:1989;197-199.
30. Watanabe J., Hayashi Y., Iwamoto K., Ozeki S. Salivary excretion of 5-fluorouracil. Fluctuation of the saliva plasma concentration ratio and salivary clearance in Beagle dogs following bolus intravenous administration. Chem Pharm Bull. 33:1985;1187-1194.
31. Hayashi Y., Watanabe J., Ozeki S., Iwamoto K. Salivary excretion of 5-fluorouracil (5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats. Chem Pharm Bull. 36:1988;4531-4547.
32. Meurman J., Laine P., Lindqvist C., Pyrhonen S., Teerennhovi L. Effect of anticancer drugs on patients with and without initially reduced saliva flow. Oral Oncol. 30B:1994;204-208.
33. Hayashi Y., Watanabe J. Salivary excretion of 5-fluorouracil (5-FU). V. Effect of 5-FU concentration in perfusate on the salivary excretion of 5-FU in perfused rat mandibular gland. Chem Pharm Bull. 38:1990;2008-2011.